See today's BioWorld
To read the full story, subscribe or sign in.

FDA approves first idiopathic hypersomnia treatment with Jazz’s Xywav

Aug. 12, 2021
By Karen Carey
With generic competition on the horizon for its older sleep disorder drug Xyrem, Jazz Pharmaceuticals plc gained an added indication for its GABA B receptor agonist Xywav as the FDA approved it for idiopathic hypersomnia.
BioWorld Drugs Regulatory Neurology/psychiatric FDA